Adulter Morbus Still

Zusammenfassung

Der adulte Morbus Still ist eine seltene entzündliche Systemerkrankung. Leitsymptome/-manifestationen sind Fieber, Arthralgien oder Arthritis, Myalgien, ein typischer Hautausschlag, Halsschmerzen, Hepatosplenomegalie, Lymphadenopathie und Serositis. Zahlreiche weitere Symptome und Organmanifestationen sind jedoch möglich. Das klinische Erscheinungsbild ist variabel und kann leicht bis lebensbedrohlich ausgeprägt sein. Der Erkrankungsverlauf ist spontan-limitierend, intermittierend oder chronisch. Da ein beweisendes diagnostisches Testverfahren nicht vorhanden ist, kann die Diagnose erst nach Ausschluss zahlreicher, vor allem infektiöser, maligner und autoimmuner Differentialdiagnosen gestellt werden. Zur Therapie können nichtsteroidale Antiphlogistika, Glucocorticoide, Basistherapeutika und Biologika eingesetzt werden.

Abstract

Adult-onset Still’s disease is a rare inflammatory systemic disease. Cardinal symptoms/manifestations are fever, arthralgias or arthritis, myalgias, the typical skin rash, sore throat, hepatosplenomegaly, lymphadenopathy and serositis. Several other symptoms and organ involvements are possible. The clinical picture is variable with mild to life-threatening courses. The disease is self-limiting, intermittently active or chronic. Because of the lack of a defined diagnostic test the diagnosis of AOSD can only be made after exclusion of several differential diagnoses in particular of infectious, malignant and autoimmune origin. For therapy non-steroidal anti-inflammatory drugs, glucocorticoids, disease modifying antirheumatic drugs and biologics can be used.

adulter Morbus Still - Morbus Still des Erwachsenen - adult-onset Still’s disease (AOSD)

Still’s disease - adult-onset Still’s disease - AOSD

Literatur

• 1 Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross W L. Successful treatment of refractory adult onset Still’s disease with rituximab.  Ann Rheum Dis. 2006;  65 1117-1118
• 2 Bagnari V, Colina M, Ciancio G, Govoni M, Trotta F. Adult-onset Still’s disease.  Rheumatol Int. 2010;  30 855-862
• 3 Benucci M, Li G F, Del Rosso A, Manfredi M. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still’s disease: the first case report.  Clin Exp Rheumatol. 2005;  23 733
• 4 Bisagni-Faure A, Job-Deslandre C, Menkes C J. Intravenous methylprednisolone pulse therapy in Still’s disease.  J Rheumatol. 1992;  19 1487-1488
• 5 Bywaters E GL. Still’s disease in the adult.  Ann Rheum Dis. 1971;  30 121-133
• 6 Dechant C, Schauenberg P, Antoni C E, Kraetsch H G, Kalden J R, Manger B. Langzeitergebnisse einer TNF-Blockade beim Morbus Still im Erwachsenenalter.  Dtsch Med Wochenschr. 2004;  129 1308-1312
• 7 Dechant C, Schulze-Koops H. Adult-Onset Still’s Disease.  Akt Rheumatol. 2008;  33 108-114
• 8 Efthimiou P, Paik P K, Bielory L. Diagnosis and management of adult onset Still’s disease.  Ann Rheum Dis. 2006;  65 564-572
• 9 Efthimiou P, Georgy S. Pathogenesis and management of adult-onset Still`s Disease.  Semin Arthritis Rheum. 2006;  36 144-152
• 10 Evensen K J, Nossent H C. Epidemiology and outcome of adult-onset Still’s disease in Northern Norway.  Scand J Rheumatol. 2006;  35 48-51
• 11 Fautrel B. Adult-onset Still disease.  Best Pract Res Clin Rheumatol. 2008;  22 773-792
• 12 Fautrel B, Sibilia J, Mariette X, Combe B. Tumour necrosis factor alpha blocking agents in refractory adult Still’s disease: an observational study of 20 cases.  Ann Rheum Dis. 2005;  64 262-266
• 13 Fautrel B, Zing E, Golmard J L P. et al . Proposal for a new set of classification criteria for adult-onset still disease.  Medicine (Baltimore). 2002;  81 194-200
• 14 Fautrel B, Le Moël G, Saint-Marcoux B. et al . Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease.  J Rheumatol. 2001;  28 322-329
• 15 Hoshino T, Ohta A, Yang D. et al . Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factos-alpha levels in patients with adult Still’s disease.  J Rheumatol. 1998;  25 396-398
• 16 Hot A, Toh M L, Coppéré B. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients.  Medicine (Baltimore). 2010;  89 37-46
• 17 Husni M E, Maier A L, Mease P J. et al . Etanercept in the treatment of adult patients with Still’s disease.  Arthritis Rheum. 2002;  46 1171-1176
• 18 Jiang L, Wang Z, Dai X, Jin X. Adult-onset Still’s disease in a Chinese population.  J Rheumatol. 2011;  38 741-746
• 19 Jung J H, Jun J B, Yoo D H. et al . High toxicity of sulfasalazine in adult-onset Still’s disease.  Clin Exp Rheumatol. 2000;  18 245-248
• 20 Kawashima M, Yamamura M, Taniai M. et al . Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still’s disease.  Arthritis Rheum. 2001;  44 550-560
• 21 Khraishi M, Fam A G. Treatment of fulminant adult Still’s disease with intravenous pulse methylprednisolone therapy.  J Rheumatol. 1991;  18 1088-1090
• 22 Kötter I, Wacker A, Koch S. et al . Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature.  Semin Arthritis Rheum. 2007;  37 189-197
• 23 Kötter I, Schedel J, Kümmerle-Deschner J B. Periodische Fiebersyndrome / autoinflammatorische Syndrome.  Z Rheumatol. 2009;  68 137-148
• 24 Laskari K, Tzioufas A G, Moutsopoulos H M. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study.  Arthritis Res Ther. 2011;  13 R91
• 25 Lequerré T, Quartier P, Rosellini D. et al . Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.  Ann Rheum Dis. 2008;  67 302-308
• 26 Manger B. Adult onset Still’s disease.  Z Rheumatol. 2008;  67 415-422
• 27 Manger B, Rech J, Schett G. Use of methotrexate in adult-onset Still’s disease.  Clin Exp Rheumatol. 2010;  28 (5 Suppl 61) S168-171
• 28 Masson C, Le Loët X, Lioté F. et al . Comparative study of 6 types of criteria in adult Still’s disease.  J Rheumatol. 1996;  62 495-497
• 29 Masson C, Le Loët X, Lioté F. et al . Adult Still’s disease. Part II. Management, outcome, and prognostic factors.  Rhev Rum Engl Ed. 1995;  62 758-765
• 30 Moulis G, Sailler L, Astudillo L, Pugnet G, Arlet P. May anakinra be used earlier in adult onset Still disease?.  Clin Rheumatol. 2010;  29 1199-1200
• 31 Naumann L, Feist E, Natusch A. et al . IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease.  Ann Rheum Dis. 2001;  69 466-467
• 32 Ohta A, Yamaguchi M, Tsunematsu T. et al . Adult Still’s disease: a multicenter survey of Japanese patients.  J Rheumatol. 1990;  17 1058-163
• 33 Perdan-Pirkmajer K, Praprotnik S, Tomi M. A case of refractory adult-onset Still’s disease successfully controlled with tocilizumab and a review of the literature.  Clin Rheumatol. 201;  29 1465-1467
• 34 Pouchot J, Sampalis J S, Beaudet F. et al . Adult Still’s disease: manifestations, disease course, and outcome in 62 patients.  Medicine. 1991;  70 118-136
• 35 Puéchal X, DeBandt M, Berthelot J M. et al . Tocilizumab in refractory adult Still’s disease.  Arthritis Care Res. 2011;  63 155-159
• 36 Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still’s disease.  Clin Exp Rheumatol. 2010;  28 265-267
• 37 Reginato A J, Schumacher Jr H R, Baker D G, O’Connor C R, Ferreiros J. Adult onset Still’s disease: experience in 23 patients and literature review with emphasis on organ failure.  Semin Arthritis Rheum. 1987;  17 39-57
• 38 Thonhofer R, Hiller M, Just H, Trummer M, Siegel C, Dejaco C. Treatment of refractory adult-onset still’s disease with tocilizumab: report of two cases and review of the literature.  Rheumatol Int. 2011; Epub Jan 15; 
• 39 Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T. et al . Preliminary criteria for classification of adult Still’s disease.  J Rheumatol. 1992;  19 424-430